Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s onc | Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress tests.
TL;DRAI
Pfizer allocates $10.5B to Innovent Biologics via a five-month multi-asset deal for 12 oncology drugs. Validates Chinese biotech innovation and marks biopharma's turn toward bundled partnerships as standard M&A strategy over single-program hunting.
1,270 words~6 min read
